Analysis of allogenic stem cell transplantation for primary immunodeficiency using TRUMP data

Analysis of allogenic stem cell transplantation for primary immunodeficiency using TRUMP data - Analysis of allo-HCT for PIDs in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033911

Enrollment

800

Registered

2018-12-01

Start date

2018-07-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary immunodeficiency

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with PID in TRUMP registration who have received HCT from January 1974 to December 2016

Exclusion criteria

Exclusion criteria: The patients whose TRUMP data are insufficient for analysis.

Design outcomes

Primary

Measure	Time frame
Overall survival/ event-free survival in patients with PID after HCT	—

Secondary

Measure	Time frame
We divide the patients into following subgroups; different periods of years, disease categories according to International Union of Immunological Societies; IUIS classification, pre-HCT status of complications; infection, autoimmune disease or autoinflammatory diseases, conditioning regimen; myeloablative, reduced intensity or nothing, and donor sources. We analyze survival, adverse events and long-term immunological reconstitution (i.e. post-transplant chimerism and secession of immunoglobulin supplementation) in each subgroup. In addition, we identify the factors contributing to survival by multivariate analysis, as well as the risks for post-HCT adverse events such as graft-versus host disease, infection or the late complications.	—

Measure

Time frame

We divide the patients into following subgroups; different periods of years, disease categories according to International Union of Immunological Societies; IUIS classification, pre-HCT status of complications; infection, autoimmune disease or autoinflammatory diseases, conditioning regimen; myeloablative, reduced intensity or nothing, and donor sources. We analyze survival, adverse events and long-term immunological reconstitution (i.e. post-transplant chimerism and secession of immunoglobulin supplementation) in each subgroup. In addition, we identify the factors contributing to survival by multivariate analysis, as well as the risks for post-HCT adverse events such as graft-versus host disease, infection or the late complications.

—

Countries

Japan

Contacts

Public ContactSatoshi Miyamoto

Tokyo Medical and Dental University Department of Pediatrics

smiyped@tmd.ac.jp03-5803-5249

Outcome results